NASDAQ / LIVE COMPANY INTELLIGENCE

Phathom Pharmaceuticals, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERPHAT
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / PHAT COVERAGE

What’s moving Phathom Pharmaceuticals, Inc. now

Current reporting with the operating signal separated from the noise.

01
PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)

PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)

The story matters when it changes Phathom Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Phathom Pharmaceuticals, Inc. (PHAT) reports break-even earnings for Q2

Phathom Pharmaceuticals, Inc. (PHAT) reports break-even earnings for Q2

Investors are testing whether Phathom Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
03
Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

The story matters when it changes Phathom Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Phathom Pharmaceuticals, Inc. (PHAT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Phathom Pharmaceuticals, Inc. (PHAT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Investors are testing whether Phathom Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
05
PHATHOM ALERT: Bragar Eagel & Squire, P.C. is Investigating Phathom Pharmaceuticals, Inc. on Behalf of Phathom Stockholders and Encourages Investors to Contact the Firm

PHATHOM ALERT: Bragar Eagel & Squire, P.C. is Investigating Phathom Pharmaceuticals, Inc. on Behalf of Phathom Stockholders and Encourages Investors to Contact the Firm

Investors are testing whether Phathom Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
06
Hedge Funds Are Selling Phathom Pharmaceuticals, Inc. (PHAT)

Hedge Funds Are Selling Phathom Pharmaceuticals, Inc. (PHAT)

The story matters when it changes Phathom Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest PHAT filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-07-30 · Period 2026-06-30SEC ↗10-QQuarterly financial reportFiled 2026-04-30 · Period 2026-03-31SEC ↗10-KAnnual financial reportFiled 2026-02-26 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-07-30 · Period 2026-07-30SEC ↗8-KMaterial company eventFiled 2026-06-23 · Period 2026-06-23SEC ↗8-KMaterial company eventFiled 2026-05-21 · Period 2026-05-19SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-07 · Period 2026-05-19SEC ↗SCHEDULE 13GOfficial SEC filingFiled 2026-07-29SEC ↗
EARNINGS / QUARTERLY TRACKER

Phathom Pharmaceuticals, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.